Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

31.96 +0.03 (+0.09%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Stoke Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
A Closer Look at 5 Analyst Recommendations For Stoke Therapeutics ↗
 
Via Benzinga
News headline image
Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Analyst Expectations For Stoke Therapeutics's Future ↗
 
Via Benzinga
News headline image
Assessing Stoke Therapeutics: Insights From 6 Financial Analysts ↗
 
Via Benzinga
News headline image
Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics to Present at Upcoming Investor Conferences in September
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday ↗
 
Via Benzinga
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
STOK Stock Earnings: Stoke Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
STOK stock results show that Stoke Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
What's Going On With Stoke Therapeutics Stock Tuesday? ↗
After the market close on Tuesday, Stoke Therapeutics announced a proposed underwritten public offering of up to $75 million of its common stock. The company also intends to grant the underwriters a... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.